CorMedix Inc. Announces Publication Of Phase 3 LOCK IT-100 Study Data In The Clinical Journal Of The American Society Of Nephrology
Portfolio Pulse from Benzinga Newsdesk
CorMedix Inc. (NASDAQ:CRMD) has announced the publication of its Phase 3 LOCK IT-100 study results in the Clinical Journal of the American Society of Nephrology. The study demonstrated a significant 71% reduction in risk of developing Catheter Related Bloodstream Infections (CRBSIs) in subjects receiving hemodialysis via central venous catheter (CVC) using DefenCath, a catheter lock solution. The company is pursuing FDA approval of DefenCath, with a target action date of November 15, 2023.
September 08, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CorMedix's Phase 3 study results showing the efficacy of DefenCath could potentially boost the company's stock as it seeks FDA approval.
The positive results from the Phase 3 study of DefenCath, and the subsequent pursuit of FDA approval, could potentially increase investor confidence in CorMedix, leading to a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100